drugset / Trial / NCT05884242
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
Timeline
- Start
- 2023-05-22
- Primary completion
- 2023-08-01
- Completion
- 2023-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.